Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Jansen, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Vernaz-Gris, M. [1 ,2 ,3 ,4 ,5 ,6 ]
DesJardins, C. [1 ,2 ,3 ,4 ,5 ,6 ]
Wong, N. [1 ,2 ,3 ,4 ,5 ,6 ]
Campone, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Cortes, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Wanders, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Shuster, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Fuseau, E. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Eisai Ltd, London, England
[2] EMF Consulting, Aix En Provence, France
[3] Eisai Res Inst, Andover, MA USA
[4] Ctr Rene Gauducheau, St Herblain, France
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] Eisai Med Res, Ridgfield Pk, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2524
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Kaufman, Peter A.
    Awada, Ahmad
    Twelves, Chris
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina E.
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 594 - U202
  • [42] Eribulin mesylate for the treatment of breast cancer
    Cigler, Tessa
    Vahdat, Linda T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (09) : 1587 - 1593
  • [43] A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study.
    Barni, Sandro
    Fontanella, Caterina
    Del Mastro, Lucia
    Livraghi, Luca
    Pizzuti, Laura
    Morritti, Maria
    Lutrino, Stefania Eufemia
    Ciccarese, Mariangela
    Garrone, Ornella
    Michelotti, Andrea
    Latorre, Agnese
    d'Onofrio, Loretta
    Pellegrino, Arianna
    Leonardi, Vita
    Iezzi, Laura
    La Verde, Nicla Maria
    Airoldi, Mario
    Pistelli, Marco
    Martella, Francesca
    Porcu, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Eribulin Mesylate (Halaven) for Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1362): : 30 - 31
  • [45] Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
    Antoinette R. Tan
    John Sarantopoulos
    Lucy Lee
    Larisa Reyderman
    Yi He
    Martin Olivo
    Sanjay Goel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1051 - 1061
  • [46] Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer
    Chabot, Isabelle
    Zhao, Qi
    Su, Yun
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (12) : 2025 - 2036
  • [47] Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
    Tan, Antoinette R.
    Sarantopoulos, John
    Lee, Lucy
    Reyderman, Larisa
    He, Yi
    Olivo, Martin
    Goel, Sanjay
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 1051 - 1061
  • [48] Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
    Shinichiro Kashiwagi
    Wakaba Fukushima
    Yuka Asano
    Wataru Goto
    Koji Takada
    Satoru Noda
    Tsutomu Takashima
    Naoyoshi Onoda
    Masahiko Ohsawa
    Kosei Hirakawa
    Masaichi Ohira
    BMC Cancer, 17
  • [49] Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
    Kashiwagi, Shinichiro
    Fukushima, Wakaba
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Noda, Satoru
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    BMC CANCER, 2017, 17
  • [50] A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
    Liu, B.
    Liu, L.
    Ran, J.
    Xie, N.
    Li, J.
    Xiao, H.
    Yang, X.
    Tian, C.
    Wu, H.
    Lu, J.
    Gao, J.
    Hu, X.
    Cao, M.
    Shui, Z.
    Hu, Z. -y.
    Ouyang, Q.
    ESMO OPEN, 2023, 8 (03)
12345